Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoRevealTM Dx Colon Cancer Assay
– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment initiation and overall testing costs, today announced that its oncoRevealTM Dx … [Read more…]
